טוען...
DESIGN AND POWERING OF CYSTIC FIBROSIS CLINICAL TRIALS USING PULMONARY EXACERBATION AS AN EFFICACY ENDPOINT
BACKGROUND: Reduction in pulmonary exacerbations is an important efficacy endpoint for CF clinical studies. Powering exacerbation endpoints requires estimation of the future exacerbation incidence in CF study populations, but rates differ across the population. METHODS: We have estimated exacerbatio...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4079110/ https://ncbi.nlm.nih.gov/pubmed/21803665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2011.07.003 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|